These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31038677)

  • 21. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.
    Wang Y; Kapoor P; Parks R; Silva-Sanchez A; Alam SM; Verkoczy L; Liao HX; Zhuang Y; Burrows P; Levinson M; Elgavish A; Cui X; Haynes BF; Schroeder H
    Immunogenetics; 2016 Feb; 68(2):145-55. PubMed ID: 26687685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
    Cardozo T; Swetnam J; Pinter A; Krachmarov C; Nadas A; Almond D; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):441-50. PubMed ID: 19320565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.
    Burke V; Williams C; Sukumaran M; Kim SS; Li H; Wang XH; Gorny MK; Zolla-Pazner S; Kong XP
    Structure; 2009 Nov; 17(11):1538-46. PubMed ID: 19913488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
    Front Immunol; 2018; 9():3163. PubMed ID: 30697215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.
    Kirby KA; Ong YT; Hachiya A; Laughlin TG; Chiang LA; Pan Y; Moran JL; Marchand B; Singh K; Gallazzi F; Quinn TP; Yoshimura K; Murakami T; Matsushita S; Sarafianos SG
    FASEB J; 2015 Jan; 29(1):70-80. PubMed ID: 25351987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
    Bell CH; Pantophlet R; Schiefner A; Cavacini LA; Stanfield RL; Burton DR; Wilson IA
    J Mol Biol; 2008 Jan; 375(4):969-78. PubMed ID: 18068724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
    Diskin R; Scheid JF; Marcovecchio PM; West AP; Klein F; Gao H; Gnanapragasam PN; Abadir A; Seaman MS; Nussenzweig MC; Bjorkman PJ
    Science; 2011 Dec; 334(6060):1289-93. PubMed ID: 22033520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
    Cale EM; Gorman J; Radakovich NA; Crooks ET; Osawa K; Tong T; Li J; Nagarajan R; Ozorowski G; Ambrozak DR; Asokan M; Bailer RT; Bennici AK; Chen X; Doria-Rose NA; Druz A; Feng Y; Joyce MG; Louder MK; O'Dell S; Oliver C; Pancera M; Connors M; Hope TJ; Kepler TB; Wyatt RT; Ward AB; Georgiev IS; Kwong PD; Mascola JR; Binley JM
    Immunity; 2017 May; 46(5):777-791.e10. PubMed ID: 28514685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced antibody affinity to Japanese encephalitis virus E protein by phage display.
    Hong WW; Yen YH; Wu SC
    Biochem Biophys Res Commun; 2007 Apr; 356(1):124-8. PubMed ID: 17350601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.
    Dondelinger M; Filée P; Sauvage E; Quinting B; Muyldermans S; Galleni M; Vandevenne MS
    Front Immunol; 2018; 9():2278. PubMed ID: 30386328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies.
    Kessler N; Zvi A; Ji M; Sharon M; Rosen O; Levy R; Gorny M; Zolla-Pazner S; Anglister J
    Protein Expr Purif; 2003 Jun; 29(2):291-303. PubMed ID: 12767822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV.
    Mitchell WM; Ding L; Gabriel J
    AIDS; 1998 Jan; 12(2):147-56. PubMed ID: 9468363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Contact Residues in Anti-HIV Neutralizing Antibody by Deep Learning.
    Kaku Y; Kuwata T; Gorny MK; Matsushita S
    Jpn J Infect Dis; 2020 May; 73(3):235-241. PubMed ID: 32009060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.